Redesigned Nylon 6 Variants with Enhanced Recyclability, Ductility, and Transparency.

Geminal (gem-) disubstitution in heterocyclic monomers is an effective strategy to enhance polymer chemical recyclability by lowering their ceiling temperatures. However, the effects of specific substitution patterns on the monomer's reactivity and the resulting polymer's properties are largely unexplored. Here we show that, by systematically installing gem-dimethyl groups onto ϵ-caprolactam (monomer of nylon 6) from the α to ϵ positions, both the redesigned lactam monomer's reactivity and the resulting gem-nylon 6's properties are highly sensitive to the substitution position, with the monomers ranging from non-polymerizable to polymerizable and the gem-nylon properties ranging from inferior to far superior to the parent nylon 6. Remarkably, the nylon 6 with the gem-dimethyls substituted at the γ position is amorphous and optically transparent, with a higher Tg (by 30 °C), yield stress (by 1.5 MPa), ductility (by 3×), and lower depolymerization temperature (by 60 °C) than conventional nylon 6.

[Corrigendum] S100A9 promotes the proliferation and invasion of HepG2 hepatocellular carcinoma cells via the activation of the MAPK signaling pathway.

Subsequently to the publication of the above article, an interested reader drew to the authors' attention that two pairs of data panels in Fig. 7D on p. 1008, showing the results from Transwell invasion assay experiments, contained overlapping sections such that these panels were likely to have been derived from the same original sources where they were intended to show the results from differently performed experiments. After having consulted their original data, the authors were able to identify that two of the data panels in Fig. 7D were inadvertently selected incorrectly; specifically, the 'GST+SB203580' and 'GST­hS100A9+PD98059' panels in this figure. The revised version of Fig. 7, showing the correct data panels for the 'GST+SB203580' and 'GST­hS100A9+PD98059' panels in Fig. 7D, is shown on the next page. The authors confirm that the errors made during the assembly of Fig. 7 did not grossly affect the major conclusions presented in this paper, and are grateful to the Editor of International Journal of Oncology for allowing them this opportunity to publish a Corrigendum. They also apologize to the readership for any inconvenience caused. [International Journal of Oncology 42: 1001-1010, 2013; DOI: 10.3892/ijo.2013.1796].

Recycling Heterogenous Catalysts for Multi-Batch Conjugated Polymer Synthesis via Direct Arylation Polymerization.

Despite the inherent sustainability direct arylation polymerization (DArP) offers through a C-H activation pathway, the use of expensive homogeneous Pd catalysts remains problematic for large-scale conjugated polymer (CP) synthesis. Herein, the first report on the recycling of heterogeneous catalysts for CP synthesis using DArP is presented. We found SiliaCat Pd-DPP to be a highly efficient and recyclable catalyst for multi-batch CP synthesis providing CPs with molecular weights (Mn) up to 82 kg/mol even after being recycled three times. Batch-to-batch variations were further optimized to afford up to five batches of polymers with a Mn of 25 ± 2.5 kg/mol without structural disparity. Significantly, this work discloses among the most sustainable CP synthesis protocols to date and presents the critical concept of catalyst-recycling to the important field of organic semiconducting polymers, which potentially enables access to truly low-cost flow chemistry for industrial-scale CP synthesis.

p-Cymene: A Sustainable Solvent that is Highly Compatible with Direct Arylation Polymerization (DArP).

For over a decade, Direct Arylation Polymerization (DArP) has been demonstrated to be an eco-friendly, facile, and low-cost alternative to conventional methodologies such as Stille polymerization for conjugated polymer synthesis. By accessing through a C-H activation pathway, DArP offers a reduction of synthetic steps while eliminating the generation of stoichiometric, highly toxic organotin byproducts. However, as the major component in these reactions, the solvents most prevalently employed for DArP are hazardous and produced from unsustainable sources, such as dimethylacetamide (DMA), tetrahydrofuran (THF), and toluene. Although the use of sustainable alternative solvents such as 2-MeTHF and cyclopentyl methyl ether (CPME) has recently emerged, drawbacks of ethereal solvents include the need for a pressurized reaction setup as well as potential peroxide formation. While aromatic solvents are superior in solubilizing conjugated polymers, very little has been done in searching for more sustainable, benign alternatives for this class of solvent. Herein, we report the application of a sustainable, naturally sourced, high-boiling aromatic solvent, p-cymene, to DArP for the first time. p-Cymene was found to display excellent solubilizing ability in the synthesis of a broad scope of alternating copolymers with Mn up to 51.3 kg/mol and yields up to 96.2%, outperforming those prepared using CPME and toluene. Structural analysis revealed the exclusion of defects in these polymers prepared using p-cymene as the solvent which, in the case of a 2,2'-bithiophene monomer, is challenging to access through the use of conventional solvents for DArP, such as DMA and toluene.

Clinical Validation of the Chinese Version of Patient Completed Caprini Risk Assessment Form.

To create and validate patient-completed Caprini risk score (CRS) tools for Chinese people. We revised Chinese patient-completed CRS form according to previously published studies. We prospectively recruited 70 internal medical patients and 70 surgical patients. The average age of these patients was 54.26 ± 15.29 years, 54.29% of them were male and 80% of them had education beyond high school. The study compared: (1) patient-completed CRS and physician-completed CRS; (2) the final value of physician-completed CRS (physician-completed CRS + body mass index) and CRS in the electronic medical record (EMR) system. Patient-completed CRS was 3.71 ± 3.63, patients spent 3.60 ± 1.24 minutes, 57.14% patients were at high-highest risk; physician-completed CRS was 3.84 ± 3.63, physicians spent 2.11 ± 1.13 minutes, 59.28% patients were at high-highest risk; the final value of physician-completed CRS was 4.12 ± 3.62, 63.58% patients were at high-highest risk; CRS value in the EMR system was 4.07 ± 3.58, 65% patients were at high-highest risk. There were strong positive correlations (P < .0001) between patient-completed CRS and physician-completed CRS (r = 0.978, κ = 0.76) and between the final value of physician-completed CRS and CRS in EMR (r = 0.994, κ = 0.97). This study successfully developed and validated a Chinese patient-completed CRS that we found can replace physician-completed CRS. This results in considerable time saving for physicians and this process should increase the percentage of patients having complete risk assessment when they are admitted to the hospital.

An Efficient Precatalyst Approach for the Synthesis of Thiazole-Containing Conjugated Polymers via Cu-Catalyzed Direct Arylation Polymerization (Cu-DArP).

Over the past decade, direct arylation polymerization (DArP) has emerged as a facile and sustainable methodology for the synthesis of conjugated polymers. Recently, we developed Cu-catalyzed DArP (Cu-DArP) as a low-cost, Pd-free synthetic pathway, which enables conjugated polymers to be synthesized with high molecular weights and minimization of defects. However, the lack of study on the use of Cu-precatalysts in small-molecule direct arylation poses significant limitations for Cu-DArP to potentially overtake conventional Pd-catalyzed methodology, such as the low solubility and stability of the previously employed CuI. Therefore, in this report, we decide to explore the utility of a well-defined, easy-to-prepare, highly soluble, and stable precatalyst, Cu(phen)(PPh3)Br, as an alternative to the CuI, 1,10-phenanthroline catalytic system previously used for Cu-DArP. Herein, we report a drastic improvement of Cu-DArP methodology for the synthesis of 5,5'-bithiazole (5-BTz)-based conjugated polymers enabled by an efficient precatalyst approach, affording polymers with good Mn (up to 16.5 kDa) and excellent yields (up to 79%). 1H NMR studies reveal the exclusion of homocoupling defects, which further verifies the excellent stability of Cu(phen)(PPh3)Br compared to CuI. Furthermore, we were able to decrease the catalyst loading from 15 mol % to only 5 mol % (Mn of 11.8 kDa, 64% yield), which is unprecedented when aryl bromides are employed for Cu-DArP. Significantly, 5-BTz was shown to be inactive under various of Pd-DArP conditions, which demonstrates the high compatibility of Cu-DArP as the only pathway for the C-H activation of the 5-BTz unit and a clear case demonstrating an advantage of Cu-DArP relative to Pd-DArP.

Sustainable Synthesis of a Fluorinated Arylene Conjugated Polymer via Cu-Catalyzed Direct Arylation Polymerization (DArP).

Direct arylation polymerization (DArP) has enabled the more sustainable synthesis of conjugated polymers through the reduction of waste, elimination of toxic and hazardous byproducts, and through the reduction of overall synthetic steps. However, DArP methodologies have almost exclusively relied on the use of noble metal catalysts, such as those with Pd, counter to the efforts toward sustainability. Herein, we report the optimized synthesis of a flourinated arylene conjugated copolymer via DArP using a low-cost, sustainable copper catalyst. Through optimization of the polymerization conditions, we are able to lower the loading of the catalyst from 50 to 5 mol %. As an example, we are able to obtain molecular weights of 16.4 kDa, accompanied by a yield of 54%, with a loading of only 5 mol % for the Cu catalyst. The synthesized polymers were characterized using 1H and 19F NMR spectroscopy, showing agreement with those previously prepared with a minimization or exclusion of defects. This work also demonstrates that Cu-catalyzed DArP methodologies can be compatible with substrates that do not possess directing groups, which can help to facilitate C-H functionalization, allowing for a broadening of substrate scope.

The melt-recrystallization behavior of highly oriented α-iPP fibers embedded in a HIPS matrix.

The melt-recrystallization behavior of α-iPP fibers embedded in an amorphous HIPS matrix has been studied by means of optical microscopy. The amorphous HIPS serving as a supporter of iPP fibers does not become involved in the nucleation and crystallization process of the molten highly oriented iPP fibers. It also does not provide any birefringence under the optical microscope with crossed polarizers. This enables the study of orientation-induced ß-iPP crystallization through a control of the melting status of the fibers. Through melting the fibers at different temperatures above 175 °C and subsequent recrystallization, some ß-iPP crystals were always produced. The content of the ß-iPP crystal depends strongly on the melting temperature and melting time of the iPP fibers. It was confirmed that melting the iPP fibers at relatively lower temperature, e.g. 176 °C, less amount of ß-iPP crystals were observed. The content of ß-iPP crystal enhances first with increasing melting temperature and then decreases with further increase of the fiber melting temperature. The ß-iPP crystallization is found to be most favorable upon melting the fibers at 178 °C for 2 min. This demonstrates the requirement of a certain chain or chain segment orientation for generating ß-iPP crystallization on the one hand, while higher orientation of the iPP chains or chain segments encourages the growth of iPP crystals in the α-form on the other hand. This has been further confirmed by varying the melting time of the fiber at different temperatures, since relaxation of the iPP molecular chains at a fixed temperature is time dependent. Moreover, the complete transformation of α-iPP fibers in some local places into ß-iPP crystals implies that the αß-transition may not be required for the orientation-induced ß-iPP crystallization.

Inactivation of the phosphatidylinositol 3-kinase/Akt pathway is involved in BMP9-mediated tumor-suppressive effects in gastric cancer cells.

Bone morphogenetic proteins (BMPs) are members of the TGF-ß superfamily signaling factors. Expression of several BMPs (BMP2, BMP4, and BMP7) is correlated to poor prognosis in gastric cancer patients. The function of BMP9, the latest discovered and most powerful osteogenetic factor, in gastric cancer is relatively unclear. In this report, we investigated the expression, function and underlying molecular mechanisms of BMP9 in gastric cancer. The results show that BMP9 expression was markedly decreased in gastric cancer tissues and cell lines. Enforced BMP9 expression in the gastric cancer cell lines SGC-7901 and MNK-45 increased apoptosis and reduced viability and migration. The in vivo function of BMP9 was evaluated in a xenograft mouse model. Tumors derived from SGC-7901 cells with enforced BMP9 expression (SGC-7901/BMP9) showed significantly reduced size and weight compared to that from control cells. Enforced BMP9 expression resulted in decreased Akt activity shown as lower levels of phosphorylation at Ser473 and Thr308 in Akt. The PI3K/Akt inhibitor LY294002 potentiated BMP9's viability and migration suppression, and apoptosis induction, which was associated with reduced expression of snail and VEGF and increased expression of E-cadherin. In addition, tumors derived from SGC-7901/BMP9 showed reduced Akt activity and VEGF expression, and increased E-cadherin expression. Therefore, our studies reveal for the first time that inhibition of the PI3K-Akt pathway is involved in the tumor suppressor effects of BMP9 in gastric cancer.

S100A6 stimulates proliferation and migration of colorectal carcinoma cells through activation of the MAPK pathways.

The S100A6 protein, a member of the S100 protein family, is overexpressed in many tumors including colorectal carcinoma (CRC). Although recent studies showed that the elevated expression of S100A6 was associated with the stage and lymphatic permeation of CRC, little is known about whether and how S100A6 contributes to CRC development. Here we investigated the S100A6 expression in CRC tissues and cell lines, and explored the molecular mechanisms underlying the role of S100A6 in CRC development by examining cell proliferation and migration in vitro, and tumorigenicity in nude mice. The results show that S100A6 expression was markedly increased in CRC tissues and cell lines compared to normal colon tissues and a normal colon mucosal epithelial cell line, respectively. Recombinant adenovirus-mediated overexpression of S100A6 or treatment with recombinant S100A6 protein in HCT116, a CRC cell line with relative low S100A6 expression, resulted in enhanced cell proliferation and migration, and the mitogen-activated protein kinase (MAPK) activation in vitro, and tumor growth in vivo. Conversely, RNAi-mediated knockdown of S100A6 in LoVo, a CRC cell line with relative high S100A6 expression, resulted in reduced cell proliferation, migration and MAPK activity. S100A6-induced proliferation was partially attenuated by an ERK inhibitor while migration was suppressed by a p38 inhibitor. Taken together, our results suggest that the cellular effects of S100A6 are mediated by the ERK and p38 MAPK pathways, and modulation of these pathways may be employed for CRC prevention and therapy.

S100A8 and S100A9 are associated with colorectal carcinoma progression and contribute to colorectal carcinoma cell survival and migration via Wnt/ß-catenin pathway.

BACKGROUND AND OBJECTIVE: S100A8 and S100A9, two members of the S100 protein family, have been reported in association with the tumor cell differentiation and tumor progression. Previous study has showed that their expression in stromal cells of colorectal carcinoma (CRC) is associated with tumor size. Here, we investigated the clinical significances of S100A8 and S100A9 in tumor cells of CRC and their underlying molecular mechanisms. METHODS: Expression of S100A8 and S100A9 in colorectal carcinoma and matching distal normal tissues were measured by reverse transcriptase polymerase chain reaction (RT-PCR), immunohistochemistry and western blot. CRC cell lines treated with the recombinant S100A8 and S100A9 proteins were used to analyze the roles and molecular mechanisms of the two proteins in CRC in vitro. RESULTS: S100A8 and S100A9 were elevated in more than 50% of CRC tissues and their expression in tumor cells was associated with differentiation, Dukes stage and lymph node metastasis. The CRC cell lines treatment with recombinant S100A8 and S100A9 proteins promoted the viability and migration of CRC cells. Furthermore, the two recombinant proteins also resulted in the increased levels of ß-catenin and its target genes c-myc and MMP7. ß-catenin over-expression in CRC cells by Adß-catenin increased cell viability and migration. ß-catenin knock-down by Adsiß-catenin reduced cell viability and migration. Furthermore, ß-catenin knockdown also partially abolished the promotive effects of recombinant S100A8 and S100A9 proteins on the viability and migration of CRC cells. CONCLUSIONS: Our work demonstrated that S100A8 and S100A9 are linked to the CRC progression, and one of the underlying molecular mechanisms is that extracellular S100A8 and S100A9 proteins contribute to colorectal carcinoma cell survival and migration via Wnt/ß-catenin pathway.

S100A9 promotes the proliferation and invasion of HepG2 hepatocellular carcinoma cells via the activation of the MAPK signaling pathway.

The S100A9 protein, a member of the S100 protein family, is often upregulated in various types of cancer, including hepatocellular carcinoma (HCC). S100A9 acts as a danger signal when secreted to the extracellular space and is thought to play an important role during tumorigenesis. Despite this fact, little is known about the effects of S100A9 in the tumor microenvironment on HCC. Therefore, in this study, we investigated the effects of exogenous S100A9 on the proliferation and invasion of HepG2 HCC cells, as well as the molecular mechanisms underlying these effects. Our results demonstrated that exogenous S100A9 promoted the proliferation, clone formation and invasion of HepG2 cells in vitro, as shown by 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltrazolium bromide (MTT), clone formation and transwell invasion assays, respectively, and also promoted tumor growth in vivo by tumorigenicity assays in nude mice. Furthermore, S100A9 increased the phosphorylation of p38 and ERK1/2 mitogen-activated protein kinases (MAPKs) in HepG2 cells. When the phosphorylation of p38 was inhibited by SB203580 (a p38 inhibitor), the S100A9-induced cell invasion was reversed; when the phosphorylation of ERK1/2 was inhibited by PD98059 (an ERK1/2 inhibitor), the S100A9-induced cell proliferation was reversed. These data suggest that the S100A9-induced proliferation and invasion of HepG2 cells are partly mediated by the activation of the MAPK signaling pathway.

A potential role for the homeoprotein Hhex in hepatocellular carcinoma progression.

Hepatocellular carcinoma (HCC), the most common primary malignant tumor of the liver, often associated with the dysregulation of transcriptional pathways involved in cell growth and differentiation. The hematopoietically expressed homeobox protein (Hhex) is an important transcription factor throughout liver development and is essential to liver bud formation and hepatoblast differentiation. Here, we report a relationship between Hhex expression and HCC. First, adenovirus-mediated Hhex delivery into the hepatoma cell line, Hepa1-6, resulted in decreased expression of several proto-oncogenes (c-Jun and Bcl2), increased expression of some tumor suppressor genes (P53 and Rb), and enhanced expression of a cluster of hepatocytic and bile ductular markers. Second, Hhex expression significantly attenuated Hepa1-6 tumorigenicity in nude mice. Third, we report a correlation between Hhex expression and the differentiation state of human HCC. In 24 cases of clinical specimens, there was a significant difference in Hhex expression between poorly differentiated HCC and well-differentiated HCC (P < 0.001). Taken together, these results indicate that Hhex is a potential candidate molecular marker for HCC pathological evaluation, suggesting a need to evaluate Hhex as a potential target for therapeutic intervention.